Nancy Krunic, Ph.D

A dynamic leader with over 25 years of experience in the global pharmaceutical and medical device industries, Nancy currently serves as the Precision Medicine Head for Diagnostic Sciences and Partnerships within the Clinical Development Function at Novartis. Since joining Novartis in 2015, Nancy has had increasing responsibilities across clinical development efforts requiring precision medicine solutions. The Precision Medicine group is accountable for developing and implementing strategies for registrational biomarkers (PhI-III), supporting global health authority submissions, innovative medicine launches and lifecycle management. The portfolio of work spans across all therapeutic modalities and Novartis Disease Units. Nancy is a core member of the Clinical Innovation Leadership Team within Clinical Development and cross-divisional Biomarker and Diagnostic Review Committees supporting the R&D pipeline. She is an Executive Committee member at BloodPac (www.bloodpac.org), a Board Observer at Freenome (www.freenome.com) and an Advisor at the Convergent Sciences Virtual Cancer Center (http://csvcc.org). Prior to joining Novartis, Nancy was the Economic Development Officer for Life Sciences at the City of Toronto, a member of the Executive Leadership Team at Luminex Corporation (a NASDAQ company) and a Senior Regulatory Scientist at LEO Pharma Inc. Her academic training at the University of Toronto earned her a B.Sc. (Physiology Specialist and Computer Sciences Minor) and Ph.D. through the Faculty of Medicine.